RAB-008b

RAB-008b is a small molecule drug candidate currently in preclinical development by RabPharma for the treatment of osteoarthritis. Designed for intra-articular administration, the compound is intended to provide localized therapeutic effects within the synovial joint, potentially acting as a disease-modifying osteoarthritis drug (DMOAD). While RabPharma's research focus often involves the modulation of pathways critical to cartilage homeostasis and joint inflammation, such as the Wnt signaling pathway, the specific molecular target for the RAB-008b variant has not been publicly disclosed. The 'b' designation likely refers to a specific optimized formulation or variant within the broader RAB-008 development program.